Want to see IN:NEULANDLAB full AI Analyst Report?
NEULANDLAB Stock Chart & Stats
₹15265.60
₹591.15(4.14%)
At close: 4:00 PM EST
₹15265.60
₹591.15(4.14%)
Day’s Range― - ―
52-Week Range₹11,500.00 - ₹19,748.40
Previous CloseN/A
Volume58.52K
Average Volume (3M)2.41K
Market Cap
₹242.70B
Enterprise Value₹217.78B
Total Cash (Recent Filing)₹1.80B
Total Debt (Recent Filing)₹2.65B
Price to Earnings (P/E)66.9
Beta1.25
Next Earnings
Jul 30, 2026EPS Estimate
60.52Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)187.17
Shares Outstanding12,829,889
10 Day Avg. Volume1,318
30 Day Avg. Volume2,408
Financial Highlights & Ratios
PEG Ratio1.06
Price to Book (P/B)8.23
Price to Sales (P/S)7.63
P/FCF Ratio-262.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)338.23
Revenue Forecast (FY)₹22.42B
Bulls Say, Bears Say
Bulls Say
Strong Operating ProfitabilitySustained net and EBIT margins through FY2024–FY2026 indicate durable operating efficiency in complex API and CDMO work. Reliable margin performance underpins long‑term cash generation, funds process R&D and scale-up, and provides resilience versus commoditized competitors.
Conservative Balance Sheet / Low LeverageLow leverage and steady equity growth provide financial flexibility to fund multi‑year CDMO projects and capital spending. With historically strong ROE (≈16–23%), the balance sheet supports strategic investments and risk absorption without immediate pressure from debt service.
Strong Revenue And EPS Growth TrendHigh revenue and EPS growth metrics reflect rising demand for APIs and contract services and successful move up the value chain. Durable top‑line expansion supports scale economics, improves fixed‑cost absorption, and strengthens negotiating leverage with large pharma clients over time.
Bears Say
Weak Cash-flow Conversion / Negative FCFNegative free cash flow in FY2026 and moderate profit‑to‑cash conversion reduce financial flexibility for capex, working capital and shareholder returns. Persistent conversion gaps can force external financing, constrain scaling of CDMO projects, and increase vulnerability during margin pressure.
Meaningful Margin CompressionA sharp gross‑margin decline suggests rising input costs or adverse product mix toward lower‑margin intermediates. Without recovery, compressed margins will materially reduce cash flow and returns, undermining the company’s ability to invest in higher‑complexity synthesis and maintain competitive differentiation.
Rising Absolute Debt In FY2026An increase in absolute debt, even with still‑low leverage ratios, heightens refinancing and liquidity risk when combined with negative FCF and margin pressure. Continued debt growth could limit ability to fund CDMO scale‑ups or respond to client timing variability without raising costs.
Neuland Laboratories Ltd. News
NEULANDLAB FAQ
What was Neuland Laboratories Ltd.’s price range in the past 12 months?
Neuland Laboratories Ltd. lowest stock price was ₹11500.00 and its highest was ₹19748.40 in the past 12 months.
What is Neuland Laboratories Ltd.’s market cap?
Neuland Laboratories Ltd.’s market cap is ₹242.70B.
When is Neuland Laboratories Ltd.’s upcoming earnings report date?
Neuland Laboratories Ltd.’s upcoming earnings report date is Jul 30, 2026 which is in 25 days.
How were Neuland Laboratories Ltd.’s earnings last quarter?
Neuland Laboratories Ltd. released its earnings results on May 12, 2026. The company reported ₹165.76 earnings per share for the quarter, beating the consensus estimate of ₹78.16 by ₹87.6.
Is Neuland Laboratories Ltd. overvalued?
According to Wall Street analysts Neuland Laboratories Ltd.’s price is currently Overvalued.
Does Neuland Laboratories Ltd. pay dividends?
Neuland Laboratories Ltd. pays a Annually dividend of ₹34 which represents an annual dividend yield of 0.08%. See more information on Neuland Laboratories Ltd. dividends here
What is Neuland Laboratories Ltd.’s EPS estimate?
Neuland Laboratories Ltd.’s EPS estimate is 60.52.
How many shares outstanding does Neuland Laboratories Ltd. have?
Neuland Laboratories Ltd. has 12,829,889 shares outstanding.
What happened to Neuland Laboratories Ltd.’s price movement after its last earnings report?
Neuland Laboratories Ltd. reported an EPS of ₹165.76 in its last earnings report, beating expectations of ₹78.16. Following the earnings report the stock price went down -3.121%.
Which hedge fund is a major shareholder of Neuland Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:NEULANDLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neuland Laboratories Ltd.
Neuland Laboratories Ltd. operates as a global developer and supplier of active pharmaceutical ingredients (APIs), distributing its products across India, Europe, the United States, and other international markets. These APIs are crucial components in treatments spanning a wide array of therapeutic areas, such as respiratory conditions (antiasthmatics), cardiovascular health, fungal infections, seizure control (anticonvulsants), central nervous system disorders, bacterial infections (fluoroquinolones, antibacterial), mental health (antipsychotic), and Parkinson's disease. Additionally, the company provides bespoke manufacturing solutions and specialized peptide synthesis services. Founded in 1984, Neuland Laboratories is headquartered in Hyderabad, India.
Technical Analysis
Aurobindo Pharma Ltd
―
Divi's Laboratories Limited
―
Glenmark Life Sciences Limited
―
Granules India Limited
―
Laurus Labs Ltd.
―